{"nctId":"NCT00824291","briefTitle":"Study Evaluating Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder","startDateStruct":{"date":"2009-02"},"conditions":["Depressive Disorder, Major"],"count":437,"armGroups":[{"label":"1","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: desvenlafaxine succinate sustained release"]},{"label":"2","type":"EXPERIMENTAL","interventionNames":["Genetic: Genotyping"]}],"interventions":[{"name":"desvenlafaxine succinate sustained release","otherNames":["Pristiq"]},{"name":"Genotyping","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Outpatient men and women, between the ages of 18 to 75 years, fluent in both written and spoken English.\n* Employed for 20 hours or more for a minimum of 1 month prior to baseline.\n* Primary diagnosis of Major Depressive Disorder with symptoms for at least 30 days prior to baseline.\n\nExclusion Criteria:\n\n* Treatment with desvenlafaxine succinate sustained release at any time in the past and/or venlafaxine (Effexor or Effexor XR) 1 year prior to baseline.\n* Treatment-resistant defined as any of the following failed treatments in the past 3 years: 3 or more previous adequate trials of \\>=2 classes of antidepressant medication, electroconvulsive therapy, or psychotherapy (2 adequate trials).\n* Current (within 12 months prior to the screening visit) psychoactive substance abuse or dependence (including alcohol), manic episode, posttraumatic stress disorder, obsessive-compulsive disorder, or a lifetime diagnosis of bipolar or psychotic disorder.\n* Clinically important abnormalities on physical examination, electrocardiogram (ECG), or laboratory evaluations.","healthyVolunteers":false,"sex":"ALL","minimumAge":"19 Years","maximumAge":"74 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Hamilton Depression Scale (HAM-D) at Week 12","description":"HAM-D, clinician-rated interview, measures presence of depressive symptoms in 17 areas (symptoms such as depressed mood, guilt feelings, suicide, sleep disturbances, anxiety levels and weight loss). Total score ranges from 0 to 52; higher scores indicate more depression. Change from baseline: mean at observation minus mean at baseline.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.61","spread":"0.45"},{"groupId":"OG001","value":"-10.50","spread":"0.60"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 12","description":"Participant rated scale was used to assess the effect of the participant's symptoms on their work/social/family life. Total scores range from 0 to 30 with higher values indicating greater disruption in the participant's work/social/family life. Individual item scores range from 0 to 10.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.41","spread":"0.48"},{"groupId":"OG001","value":"-8.08","spread":"0.63"}]}]}]},{"type":"SECONDARY","title":"Clinical Global Impression Scale - Improvement (CGI- I) Score at Week 12","description":"CGI-I: 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale. Higher score = more affected. Change = score at observation minus score at baseline.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"103","spread":"0.07"},{"groupId":"OG001","value":"31","spread":"0.10"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84","spread":null},{"groupId":"OG001","value":"44","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53","spread":null},{"groupId":"OG001","value":"31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinical Global Impressions Scale - Severity of Illness (CGI-S) at Week 12","description":"CGI-S: 7-point clinician rated scale to assess severity of participant's current illness state; range: 1 (normal - not ill at all) to 7 (among the most extremely ill patients). Higher score = more affected. Change: score at observation minus score at baseline.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69","spread":"0.08"},{"groupId":"OG001","value":"23","spread":"0.11"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68","spread":null},{"groupId":"OG001","value":"30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77","spread":null},{"groupId":"OG001","value":"31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56","spread":null},{"groupId":"OG001","value":"43","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline on Work and Activities Item of HAM-D17 at Week 12","description":"The Work and Activities Item of the HAM-D17 is item 7 of HAM-D17. Scoring range from 0 to 4.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.68","spread":"0.07"},{"groupId":"OG001","value":"-1.45","spread":"0.10"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Adjusted Mean on Montgomery-Asberg Depression Rating Scale (MADRS) at Week 12","description":"Measures the overall severity of depressive symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-18.44","spread":"0.69"},{"groupId":"OG001","value":"-16.18","spread":"0.94"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline on Worry Anxiety Tension Scale (WATS) at Week 12","description":"WATS: a self-administered, 3-question rating scale assesses worry, anxiety, and tension. Each item was a visual analog scale on which the participant circles a number from 0 to 10. Higher scores indicated worse function. WATS total score was the sum of the 3 items. If 1 item was missing, the total score would be missing.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.39","spread":"0.79"},{"groupId":"OG001","value":"-10.95","spread":"1.04"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline on Stress and Social Support Scales at Week 12","description":"Stress and Social Support Scales: self-administered rating scale where item 1 is the stress vulnerability scale measuring how much the subject was set back by stressful events on an 11-point scale ranging from 0 (not at all) to 10 (extremely) and item 2 is an 11-point scale ranging from 0 to 100 percent of the amount of support the subject received from relatives and friends.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.53","spread":"0.18"},{"groupId":"OG001","value":"-2.14","spread":"0.23"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":285},"commonTop":["Nausea","Headache","Dry mouth","Dizziness","Constipation"]}}}